Eton Pharmaceuticals, Inc. (ETON) |
| 27.12 1.07 (4.11%) 04-14 16:00 |
| Open: | 26.3 |
| High: | 27.14 |
| Low: | 26.05 |
| Volume: | 261,096 |
| Market Cap: | 740(M) |
| PE Ratio: | -159.53 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 31.76 |
| Resistance 1: | 27.19 |
| Pivot price: | 24.95 |
| Support 1: | 20.70 |
| Support 2: | 16.69 |
| 52w High: | 27.19 |
| 52w Low: | 13.09 |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
| EPS | -0.170 |
| Book Value | 0.970 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.753 |
| Profit Margin (%) | -5.76 |
| Operating Margin (%) | 20.99 |
| Return on Assets (ttm) | 3.6 |
| Return on Equity (ttm) | -18.2 |
Wed, 08 Apr 2026
Eton Pharmaceuticals (NASDAQ:ETON) Hits New 1-Year High - Time to Buy? - MarketBeat
Thu, 02 Apr 2026
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tue, 31 Mar 2026
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Down 14.4% in March - MarketBeat
Tue, 24 Mar 2026
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Thu, 19 Mar 2026
Eton Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Thu, 19 Mar 2026
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |